Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Oxycodone
Drug ID BADD_D01645
Description Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917.[A178696] It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The first oxycodone containing product, Percodan, was approved by the FDA on April 12, 1950.[L6460]
Indications and Usage Oxycodone is indicated for the treatment of moderate to severe pain.[Label] There is also an extended release formulation indicated for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label]
Marketing Status approved; illicit; investigational
ATC Code N02AA05
DrugBank ID DB00497
KEGG ID D05312
MeSH ID D010098
PubChem ID 5284603
TTD Drug ID D07WPQ
NDC Product Code 71335-0981; 67651-0304; 67651-0305; 67651-0306; 24510-140; 71335-1080; 0904-6966; 24510-130; 65162-048; 67877-625; 71335-0677; 65162-050; 0904-7180; 65162-047; 72162-1812; 67877-623; 67651-0302; 65162-049; 67651-0303; 65162-051; 24510-110; 24510-115; 71335-1023; 24510-120; 72162-1811
UNII CD35PMG570
Synonyms Oxycodone | Dihydrone | Oxycone | Dihydrohydroxycodeinone | Oxycodeinon | Eucodal | Theocodin | Oxycodone Hydrochloride | Oxycontin | Pancodine | Dinarkon | Oxiconum
Chemical Information
Molecular Formula C18H21NO4
CAS Registry Number 76-42-6
SMILES CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Disturbance in attention19.21.02.002; 17.03.03.001--
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Dreamy state17.12.02.0010.000021%Not Available
Drug abuse19.07.06.0100.004826%Not Available
Drug dependence19.07.06.0110.250866%Not Available
Drug interaction08.06.03.001--Not Available
Drug withdrawal syndrome19.07.06.013; 08.06.02.0040.116127%Not Available
Drug withdrawal syndrome neonatal19.07.06.014; 08.06.02.008; 18.04.13.0010.002801%Not Available
Dry mouth07.06.01.002--
Dry skin23.03.03.001--
Dysarthria19.19.03.001; 17.02.08.001--
Dysgeusia17.02.07.003; 07.14.03.001--
Dyspepsia07.01.02.001--
Dysphagia07.01.06.003--
Dysphoria19.04.02.004--Not Available
Dyspnoea02.11.05.003; 22.02.01.004--
Dysuria20.02.02.002--
Ear disorder04.03.01.001--Not Available
Electrocardiogram ST segment depression13.14.05.005--Not Available
Emotional disorder19.04.02.005--Not Available
Endocrine disorder05.09.01.001--Not Available
Epistaxis24.07.01.005; 22.04.03.001--
Eructation07.01.02.003--
Euphoric mood19.04.02.006--
Eye disorder06.08.03.001--Not Available
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.003--
Facial paralysis17.04.03.008--Not Available
Fatigue08.01.01.002--
Fear19.06.03.001--Not Available
Feeling abnormal08.01.09.014--Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 16 Pages